Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Joerger

Showing results (1-10 of 140) with videos related to

Pageof 14
Sort By:
The AAPS Journal|January 26, 2012
Covariate pharmacokinetic model building in oncology and its potential clinical relevanceMarkus Joerger
Cancer Chemotherapy and Pharmacology|November 22, 2015
Treatment regimens of classical and newer taxanesMarkus Joerger
Expert Opinion on Drug Metabolism & Toxicology|November 15, 2014
Metabolism of the taxanes including nab-paclitaxelMarkus Joerger
Therapeutische Umschau. Revue Therapeutique|September 10, 2019
[Molecularly-targeted anticancer treatments - a short appraisal]Markus Joerger
Praxis|January 8, 2014
[Role of individualized dosing in oncology: are we there yet?]Markus Joerger
Expert Opinion on Drug Metabolism & Toxicology|January 19, 2011
Dose-toxicity models in oncologyMichel Adamina, Markus Joerger
Cancer Management and Research|February 9, 2011
Cancer chemotherapy: targeting folic acid synthesisNicole Hagner, Markus Joerger
Breast (Edinburgh, Scotland)|November 17, 2009
Update of the BIG 1-98 Trial: where do we stand?Markus Joerger, Beat Thürlimann
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 7, 2012
Diagnostic and prognostic use of bone turnover markersMarkus Joerger, Jens Huober
Expert Review of Anticancer Therapy|February 15, 2013
Chemotherapy regimens in early breast cancer: major controversies and future outlookMarkus Joerger, Beat Thürlimann
Pageof 14

Showing results (1-10 of 140) with videos related to

Sort By:
Pageof 14
The AAPS Journal|January 26, 2012
Covariate pharmacokinetic model building in oncology and its potential clinical relevanceMarkus Joerger
Cancer Chemotherapy and Pharmacology|November 22, 2015
Treatment regimens of classical and newer taxanesMarkus Joerger
Expert Opinion on Drug Metabolism & Toxicology|November 15, 2014
Metabolism of the taxanes including nab-paclitaxelMarkus Joerger
Therapeutische Umschau. Revue Therapeutique|September 10, 2019
[Molecularly-targeted anticancer treatments - a short appraisal]Markus Joerger
Praxis|January 8, 2014
[Role of individualized dosing in oncology: are we there yet?]Markus Joerger
Expert Opinion on Drug Metabolism & Toxicology|January 19, 2011
Dose-toxicity models in oncologyMichel Adamina, Markus Joerger
Cancer Management and Research|February 9, 2011
Cancer chemotherapy: targeting folic acid synthesisNicole Hagner, Markus Joerger
Breast (Edinburgh, Scotland)|November 17, 2009
Update of the BIG 1-98 Trial: where do we stand?Markus Joerger, Beat Thürlimann
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 7, 2012
Diagnostic and prognostic use of bone turnover markersMarkus Joerger, Jens Huober
Expert Review of Anticancer Therapy|February 15, 2013
Chemotherapy regimens in early breast cancer: major controversies and future outlookMarkus Joerger, Beat Thürlimann
Pageof 14